BC
Birchview Capital Portfolio holdings
AUM
$101M
This Quarter Return
+14.45%
1 Year Return
+34.62%
3 Year Return
+103.2%
5 Year Return
+107.72%
10 Year Return
+352.1%
AUM
$128M
AUM Growth
+$128M
(+8.6%)
Cap. Flow
+$4.59M
Cap. Flow
% of AUM
3.59%
Top 10 Holdings %
Top 10 Hldgs %
70.42%
Holding
59
New
8
Increased
11
Reduced
8
Closed
1
Top Buys
| 1 |
SILK
Silk Road Medical, Inc. Common Stock
SILK
|
$1.43M |
| 2 |
Phreesia
PHR
|
$741K |
| 3 |
Stoke Therapeutics
STOK
|
$658K |
| 4 |
10x Genomics
TXG
|
$504K |
| 5 |
Coherus Oncology, Inc. Common Stock
CHRS
|
$366K |
Top Sells
| 1 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$836K |
| 2 |
Bristol-Myers Squibb
BMY
|
$718K |
| 3 |
BLUE
bluebird bio
BLUE
|
$185K |
| 4 |
TSVT
2seventy bio
TSVT
|
$171K |
| 5 |
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
|
$122K |
Sector Composition
| 1 | Healthcare | 95.37% |
| 2 | Energy | 4.62% |
| 3 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Castle Biosciences
CSTL
$696M
| $216K | 0.17% |
+10,000
| New | +$216K |
|
52
Wave Life Sciences
WVE
$1.53B
| $202K | 0.16% |
+40,000
| New | +$202K |
|
53
Gossamer Bio
GOSS
$562M
| $126K | 0.1% |
138,176
-70,912
| -34% | -$64.7K |
|
54
BioCryst Pharmaceuticals
BCRX
$1.74B
| $120K | 0.09% |
20,000
| – | – |
|
|
TSVT
55
DELISTED
2seventy bio
TSVT
| $84.7K | 0.07% |
19,833
-40,000
| -67% | -$171K |
|
56
InflaRx
IFRX
$108M
| $81.5K | 0.06% |
50,000
| – | – |
|
57
Ventyx Biosciences
VTYX
$171M
| $71.1K | 0.06% |
28,800
+2,400
| +9% | +$5.93K |
|
|
YTEN
58
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
| $4.49K | ﹤0.01% |
18,750
| – | – |
|
59
Nektar Therapeutics
NKTR
$568M
| – | – |
-28,000
| Closed | -$16.7K |
|